AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the ...

Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

AMd (AMD) said via X that it is partnering with drug-discovery company Absci (ABSI). “AMD is proud to announce we are partnering with @abscibio ...

AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design ...

Investing.com -- Shares of Absci Corporation (NASDAQ: ABSI) soared 50% following the announcement of a strategic ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD ...

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.

Shares of Absci on Wednesday jumped following a report on a $20 million investment from Advanced Micro Devices. The stock was up 27% to $3.89 in pre-market trading. Through Tuesday's close, shares ...